Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objective: To synthesise existing knowledge of the efficacy and safety of long-acting versus short-acting methylphenidate for paediatric attention deficit hyperactivity disorder (ADHD). Design: Systematic review and meta-analysis. Data sources: Electronic literature search of CENTRAL, MEDLINE, PreMEDLINE, CINAHL, EMBASE, PsychINFO, Scopus and Web of Science for articles published in the English language between 1950 and 2012. Reference lists of included studies were checked for additional studies. Study selection: Randomised controlled trials of paediatric ADHD patients (<18 years), comparing a long-acting methylphenidate form to a short-acting methylphenidate form. Data extraction: Two authors independently selected trials, extracted data and assessed risk of bias. Continuous outcomes were compared using standardised mean differences (SMDs) between treatment groups. Adverse events were compared using risk differences between treatment groups. Heterogeneity was explored by subgroup analysis based on the type of long-acting formulation used. Results: Thirteen RCTs were included; data from 882 participants contributed to the analysis. Meta-analysis of three studies which used parent ratings to report on hyperactivity/impulsivity had an SMD of −0.30 (95% CI −0.51 to −0.08) favouring the long-acting forms. In contrast, three studies used teacher ratings to report on hyperactivity and had an SMD of 0.29 (95% CI 0.05 to 0.52) favouring the short-acting methylphenidate. In addition, subgroup analysis of three studies which used parent ratings to report on inattention/overactivity indicate that the osmotic release oral system generation long-acting formulation was favoured with an SMD of −0.35 (95% CI −0.52 to −0.17), while the second generation showed less efficacy than the short-acting formulation with an SMD of 0.42 (95% CI 0.17 to 0.68). The long-acting formulations presented with slightly more total reported adverse events (n=578) as compared with the short-acting formulation (n=566). Conclusions: The findings from this systematic review indicate that the long-acting forms have a modest effect on the severity of inattention/overactivity and hyperactivity/impulsivity according to parent reports, whereas the short-acting methylphenidate was preferred according to teacher reports for hyperactivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impairment of social and moral behavior related to early damage in human prefrontal cortex
Anderson, S. W., Bechara, A., Damasio, H., Tranel, D., & Damasio, A. R. (1999) · Nature Neuroscience · doi:10.1038/14833 · Cited by 1,539 · cited 1×
“Evidence has suggested that ADHD may be the result of insufficient production of norepinephrine and dopamine in the prefrontal cortex,(6) resulting in forgetfulness, distractibility, impulsivity and inappropriate social behaviours.(7) By increasing”
BackgroundCommittee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Grey literature in meta-analyses of randomized trials of health care interventions
Hopewell, S., McDonald, S., Clarke, M. J., & Egger, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000010.pub3 · Cited by 598
Biederman, J., Faraone, S. V., Spencer, T. J., Mick, E., Monuteaux, M. C., & Aleardi, M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0403 · Cited by 565
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Stimulants: Therapeutic Actions in ADHD
Arnsten, A. F. T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301164 · Cited by 473
Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378
Risk of bias versus quality assessment of randomised controlled trials: cross sectional study
Hartling, L., Ospina, M., Liang, Y., Dryden, D. M., Hooton, N., Krebs Seida, J., & Klassen, T. P. (2009) · BMJ · doi:10.1136/bmj.b4012 · Cited by 348
Self-citationMedication treatment strategies in the MTA Study: relevance to clinicians and researchers
GREENHILL, L. L., ABIKOFF, H. B., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., ELLIOTT, G., HECHTMAN, L., HINSHAW, S. P., HOZA, B., JENSEN, P. S., et al. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00017 · Cited by 297
A Clinical Perspective of Attention-Deficit/Hyperactivity Disorder Into Adulthood
Wilens, T. E., & Dodson, W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1003 · Cited by 274
Pelham, W. E., Sturges, J., Hoza, J., Schmidt, C., Bijlsma, J. J., Milich, R., & Moorer, S. (1987) · PEDIATRICS · doi:10.1542/peds.80.4.491 · Cited by 167
Schachar, R., Ickowicz, A., Crosbie, J., Donnelly, G. A. E., Reiz, J. L., Miceli, P. C., Harsanyi, Z., & Darke, A. C. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0039 · Cited by 43
Cited by
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Storebø, O. J., Krogh, H. B., Ramstad, E., Moreira-Maia, C. R., Holmskov, M., Skoog, M., Nilausen, T. D., Magnusson, F. L., Zwi, M., Gillies, D., et al. (2015) · BMJ · doi:10.1136/bmj.h5203 · Cited by 209
Tamminga, H. G. H., Reneman, L., Huizenga, H. M., & Geurts, H. M. (2016) · Psychological Medicine · doi:10.1017/s0033291716000350 · Cited by 82
“2004, 2005) and MPH formulation (Punja et al. 2013) are additional potential moderators of the effects of stimulants.”
BackgroundResultADHD and hyperkinetic disorder
Sonuga‐Barke, E. J. S., & Taylor, E. (2015) · Rutter's Child and Adolescent Psychiatry · doi:10.1002/9781118381953.ch55 · Cited by 62
Holmskov, M., Storebø, O. J., Moreira-Maia, C. R., Ramstad, E., Magnusson, F. L., Krogh, H. B., Groth, C., Gillies, D., Zwi, M., Skoog, M., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0178187 · Cited by 58
Metadata
- Authors
- Punja, S., Zorzela, L., Hartling, L., Urichuk, L., & Vohra, S.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013
- Volume
- 3
- Issue
- 3
- Pages
- e002312
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2147944416
- Cited by
- 40
- References
- 13
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.